Press-release for stocks in the health technology sector

Prices are updated after-hours

Phio Pharmaceuticals Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Published: 2023-04-20 (Crawled : 19:00) - investors.phiopharma.com
PHIO | News | $0.672 -4.0% -4.17% 91K

| -83.74% | O: 2.18% H: 0.0% C: -8.55%
nasdaq direct offering pharmaceuticals

Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Published: 2023-04-18 (Crawled : 17:00) - investors.phiopharma.com
PHIO | News | $0.672 -4.0% -4.17% 91K

| -88.98% | O: -3.95% H: 110.1% C: -15.92%
nasdaq direct offering pharmaceuticals

Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity
Published: 2023-04-17 (Crawled : 12:00) - investors.phiopharma.com
PHIO | News | $0.672 -4.0% -4.17% 91K

| -86.94% | O: 10.3% H: 17.14% C: 7.42%
ph-762 cell pharmaceuticals preclinical study

Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update
Published: 2023-03-22 (Crawled : 22:00) - investors.phiopharma.com
PHIO | News | $0.672 -4.0% -4.17% 91K

| -87.48% | O: 6.54% H: 5.26% C: 1.58%
business year update pharmaceuticals financial results

Phio Pharmaceuticals Announces Reverse Stock Split
Published: 2023-01-25 (Crawled : 14:00) - investors.phiopharma.com
PHIO | News | $0.672 -4.0% -4.17% 91K

| -89.66% | O: -7.39% H: 14.2% C: 1.02%
pharmaceuticals

Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma
Published: 2022-12-21 (Crawled : 22:00) - investors.phiopharma.com
PHIO | News | $0.672 -4.0% -4.17% 91K

| -85.11% | O: 9.33% H: 0.0% C: -12.49%
ph-762 treatment pharmaceuticals program study cell carcinoma

Phio Announces New Appointments to Leadership Team, Reports on Third Quarter 2022 Financial Results and Provides Business Update
Published: 2022-11-10 (Crawled : 23:00) - investors.phiopharma.com
SNY | News | $46.66 -2.16% -2.21% 1.7M

| 4.37% | O: -3.62% H: 0.0% C: 0.0%
PHIO | News | $0.672 -4.0% -4.17% 91K

| -89.66% | O: 1.85% H: 0.0% C: -12.69%
financial update results

| -90.4% | O: 6.63% H: 3.0% C: -12.9%
pharmaceuticals immunotherapy meeting cancer study

Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman
Published: 2022-09-29 (Crawled : 13:00) - investors.phiopharma.com
PHIO | News | $0.672 -4.0% -4.17% 91K

| -90.73% | O: -2.06% H: 2.52% C: -3.2%
pharmaceuticals

Phio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Published: 2022-08-11 (Crawled : 21:00) - investors.phiopharma.com
PHIO | News | $0.672 -4.0% -4.17% 91K

| -92.73% | O: 0.27% H: 0.01% C: -3.88%
update results

Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022
Published: 2022-05-16 (Crawled : 12:00) - investors.phiopharma.com
PHIO | News | $0.672 -4.0% -4.17% 91K

| -2.19% | O: 3.49% H: 6.15% C: 0.3%
ph-894 ph94 her2- her2

Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
Published: 2022-05-12 (Crawled : 16:20) - investors.phiopharma.com
PHIO | News | $0.672 -4.0% -4.17% 91K

| -3.18% | O: -1.01% H: 0.0% C: 0.0%
results

Phio Pharmaceuticals Selected to Present at the Tumor Immune Microenvironment Workshop of the Society for Immunotherapy of Cancer
Published: 2022-04-18 (Crawled : 14:00) - investors.phiopharma.com
PHIO | News | $0.672 -4.0% -4.17% 91K

| -43.7% | O: -5.04% H: 24.78% C: 9.73%
immunotherapy cancer

Phio Pharmaceuticals Announces Upcoming Presentation at the SITC 36th Annual Meeting
Published: 2021-10-18 (Crawled : 15:00) - investors.phiopharma.com
PHIO | News | $0.672 -4.0% -4.17% 91K

| -59.88% | O: 1.8% H: 0.59% C: -1.76%
presentation